(Reuters) – Drugmaker Emergent BioSolutions said on Monday that it would reduce its workforce in Lansing, Michigan, by up to 70 roles as part of its ongoing restructuring efforts.
The Gaithersburg, Maryland-based company has been cutting costs and pivoting away from its contract manufacturing business due to sluggish demand and a focus on driving sales growth for its opioid overdose reversal drug Narcan and other branded drugs.
In May, Emergent cut about 300 jobs and shut down a drug substance manufacturing facility in Baltimore, Bayview and a drug product facility in Rockville, Maryland.
The Lansing site serves as a hub for its drug substance manufacturing capabilities, as well as other critical projects.
The affected roles were related to manufacturing and site operations, and about 155 employees will remain at the plant that primarily manufactures anthrax vaccines, BioThrax and Cyfendus for the U.S. government, the company told Reuters.
(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
Comments